Projects per year
Personal profile
Area of Expertise
My laboratory works on the development of endothelin receptor antagonists as neuroprotective agents for the treatment of glaucoma. Glaucoma is often referred to as the “sneak thief of sight” since the disease generally produces minimal pain or discomfort. Glaucoma is an optic neuropathy, commonly associated with an elevation of intraocular pressure, resulting in the degeneration of the optic nerve and loss of retinal ganglion cells, which could lead to loss of vision. Currently, the mainstay of glaucoma treatment is reduction in intraocular pressure, however, neurodegenerative effects persist in some patients. Hence, there is an unmet need for neuroprotective treatments for glaucoma.
Our prior studies have shown that endothelin receptors are increased in a rodent model of glaucoma and contribute to damage to the optic nerve and death of retinal ganglion cells. We are currently testing endothelin receptor antagonists for their ability to promote neuroprotection, following elevation of intraocular pressure in rats. The long term goal is to understand mechanisms by which a blockade of the endothelin receptor could promote neuroprotection and develop neuroprotective treatments for glaucoma patients.
Our prior studies have shown that endothelin receptors are increased in a rodent model of glaucoma and contribute to damage to the optic nerve and death of retinal ganglion cells. We are currently testing endothelin receptor antagonists for their ability to promote neuroprotection, following elevation of intraocular pressure in rats. The long term goal is to understand mechanisms by which a blockade of the endothelin receptor could promote neuroprotection and develop neuroprotective treatments for glaucoma patients.
Education/Academic qualification
BS in Chemistry, University of Bombay
MS in Biochemistry, University of Bombay
PhD in Biochemistry, University of Bombay
Fingerprint
Dive into the research topics where Raghu Krishnamoorthy is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Mechanisms underlying endothelin mediated neurodegeneration in glaucoma
Krishnamoorthy, R. & KRISHNAMOORTHY, R.
30/09/17 → 31/08/22
Project: Research
-
Texas Center of Minority Health, Education, Research and Outreach - Admin/Development Core
Vishwanatha, J., Jones, H., He, J., Basha, R., Nandy, K., Mallet, R., Krishnamoorthy, R. & Simecka, J.
NIMHD: Natl Institute on Minority Health
23/09/17 → 31/05/22
Project: Research
-
Texas Center of Minority Health, Education, Research and Outreach - Admin/Development Core
Vishwanatha, J., Mallet, R., Krishnamoorthy, R., Jones, H., Fulda, K., He, J., Basha, R. & Nandy, K.
NIMHD: Natl Institute on Minority Health
23/09/17 → 31/05/22
Project: Research
-
-
Mechanisms underlying endothelin mediated neurodegeneration in glaucoma
30/09/17 → 31/08/21
Project: Research
-
Involvement of c-Jun N-terminal kinase 2 (JNK2) in endothelin-1 (ET-1) mediated neurodegeneration of retinal ganglion cells
Kodati, B., Stankowska, D. L., Krishnamoorthy, V. R. & Krishnamoorthy, R. R., May 2021, In: Investigative Ophthalmology and Visual Science. 62, 6, 13.Research output: Contribution to journal › Article › peer-review
Open Access -
Nanoencapsulated hybrid compound sa-2 with long-lasting intraocular pressure–lowering activity in rodent eyes
Stankowska, D. L., Millar, J. C., Kodati, B., Behera, S., Chaphalkar, R. M., Nguyen, T., Nguyen, K. T., Krishnamoorthy, R. R., Ellis, D. Z. & Acharya, S., 2021, In: Molecular vision. 27, p. 37-49 13 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Endothelin-1 Mediated Decrease in Mitochondrial Gene Expression and Bioenergetics Contribute to Neurodegeneration of Retinal Ganglion Cells
Chaphalkar, R. M., Stankowska, D. L., He, S., Kodati, B., Phillips, N., Prah, J., Yang, S. & Krishnamoorthy, R. R., 1 Dec 2020, In: Scientific Reports. 10, 1, 3571.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Correction: Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: implications for neuroprotection in glaucoma (Cell Death Discovery, (2019), 5, 1, (112), 10.1038/s41420-019-0194-2)
Stankowska, D. L., Nam, M. H., Nahomi, R. B., Chaphalkar, R. M., Nandi, S. K., Fudala, R., Krishnamoorthy, R. R. & Nagaraj, R. H., 1 Dec 2019, In: Cell Death Discovery. 5, 1, 122.Research output: Contribution to journal › Comment/debate
Open Access -
Systemically administered peptain-1 inhibits retinal ganglion cell death in animal models: Implications for neuroprotection in glaucoma
Stankowska, D. L., Nam, M. H., Nahomi, R. B., Chaphalkar, R. M., Nandi, S. K., Fudala, R., Krishnamoorthy, R. R. & Nagaraj, R. H., 2019, In: Cell Death Discovery. 5, 1, 112.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations